ArticleBlood cell therapy2026
Etanercept in Steroid-Refractory Acute Graft Versus Host Disease: Clinical Response, Toxicity, and Long-Term Outcomes.
Article in Blood cell therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Steroid refractory acute graft versus host disease (SR-aGVHD) is seen in 30%-40% of patients undergoing allogeneic hematopoietic stem cell transplant (allo HSCT). We report our experience with etanercept (ETA) as a first-line treatment for SR-aGVHD during a period when ruxolitinib was not available in India. We retrospectively analysed 43 allo HSCT patients from 2010 to 2019 who received ETA for SR-aGVHD. The primary objective was to assess the overall response rate with etanercept. Secondary objectives included overall survival (OS), organ specific responses, causes of mortality and identification of factors associated with survival and see its utility in the current ruxolitinib era. The response rates (overall response rate [ORR] - complete response [CR] + very good partial response [VGPR] + partial response [PR]) at Day 28 was 69%. The organ-specific ORR was 70% (lower gut), 67% (skin), and 50% (liver). The median OS of responders at Day 28 from ETA start was 6.8 months versus 2.8 months in non-responders (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.